arrow-down arrow-left arrow-open-down arrow-open-up arrow-right arrow-up close documents dot-arrow-down dot-arrow-right facebook fb-square google instagram linkedin menu search twitter whatsapp


MSF is focusing on implementing new regimens for patients with multidrug-resistant tuberculosis (MDR-TB) in Armenia, which has one of the highest rates of the disease in the world.



patients started treatment for TB, of which 66 for MDR-TB

Tuberculosis continues to be a major public health concern in Armenia. The incidence of drug-sensitive TB is estimated at 41 new cases per 100,000 people per year, while 11 per cent of new cases and 47 per cent of previously treated cases are drug-resistant. Around 10 per cent of MDR-TB patients have the extensively drug-resistant (XDR) form of the disease. The main challenge when treating MDR-TB patients is the length and toxicity of the regimen itself – it involves taking up to 20 tablets every day for two years, and months of painful daily injections. For some patients, a port-a-cath is implanted to ease the twice-daily intravenous injections. Permanent hearing loss, suicidal depression and psychosis are among the side effects of the treatment, which is only successful for around half of MDR-TB patients and a quarter of those with XDR-TB.

Armenia was one of the first countries in the world to authorise the use of two new TB drugs, bedaquiline and delamanid, which promise to be less toxic and more effective. In 2016, this continued to be the focus of MSF activities in Armenia, and care of patients on standard MDR-TB treatment was handed over to the Armenian authorities.

Between January and December 2016, 66 MDR-TB patients started the new regimen, and a total of 79 patients were under treatment by the end of the year.


No. staff in 2016: 43 | Expenditure: €1.8 million | Year MSF first worked in the country: 1988 |